Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Population Health Research Institute
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06587737CT.gov Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage | — | Not Yet Recruiting | — | — | — |
NCT07035405CT.gov Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX) | — | Not Yet Recruiting | — | — | — |
NCT06763055CT.gov The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL | — | Recruiting | — | — | — |
NCT06352632CT.gov ACT-GLOBAL Adaptive Platform Trial for Stroke | — | Recruiting | — | — | — |
NCT05476991CT.gov Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Stroke Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Colchicinum (this asset) | Population Health Research Institute | P3 | B · 57 |
| Incobotulinumtoxina | Parc de Salut Mar | P4 | BBB |
| Aggrenox | Boehringer Ingelheim | P4 | BBB |
| Atenolol | Northern California Institute of Research and Education | P4 | BBB |
| Dextromethorphan | University of Florida | P4 | BBB |
| Tenecteplase | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Nerinetide | NoNO Inc. | P3 | BBB |
| Rivaroxaban | China National Center for Cardiovascular Diseases | P4 | BBB |
| Aspirin | China National Center for Cardiovascular Diseases | P4 | BB |
+42 more in the Stroke Disorder cohort
Other indications for Colchicinum
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cirrhosis Of Liver | — | P4 | BBB · 72 |
| Fibrotic Liver Disease | — | P4 | BB · 69 |
| Hepatitis C Virus Infection | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Colchicinum in Stroke Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/colchicinum-stroke-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →